<!DOCTYPE html>
<!--
==============================================================================
           "GitHub HTML5 Pandoc Template" v2.1 — by Tristano Ajmone           
==============================================================================
Copyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:

- https://github.com/tajmone/pandoc-goodies

The CSS in this template reuses source code taken from the following projects:

- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):
  https://github.com/sindresorhus/github-markdown-css

- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):
  http://primercss.io/

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The MIT License 

Copyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)
Copyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)
Copyright (c) 2017 GitHub Inc.

"GitHub Pandoc HTML5 Template" is Copyright (c) Tristano Ajmone, 2017, released
under the MIT License (MIT); it contains readaptations of substantial portions
of the following third party softwares:

(1) "GitHub Markdown CSS", Copyright (c) Sindre Sorhus, MIT License (MIT).
(2) "Primer CSS", Copyright (c) 2016 GitHub Inc., MIT License (MIT).

Permission is hereby granted, free of charge, to any person obtaining a copy
of this software and associated documentation files (the "Software"), to deal
in the Software without restriction, including without limitation the rights
to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
copies of the Software, and to permit persons to whom the Software is
furnished to do so, subject to the following conditions:

The above copyright notice and this permission notice shall be included in all
copies or substantial portions of the Software.

THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
SOFTWARE.
==============================================================================-->
<html>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>Nephrotic Syndrome MeG-CLS-061</title>
  <style type="text/css">
@charset "UTF-8";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,"Segoe UI",Helvetica,Arial,sans-serif,"Apple Color Emoji","Segoe UI Emoji","Segoe UI Symbol";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:""}.markdown-body hr::after{display:table;clear:both;content:""}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:" "}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:""}.markdown-body::after{display:table;clear:both;content:""}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}
  </style>
  <style type="text/css">code{white-space: pre;}</style>
  <!--[if lt IE 9]>
    <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js"></script>
  <![endif]-->
</head>
<body>
<article class="markdown-body">
<h1 id="nephrotic-syndrome">Nephrotic syndrome </h1>
<h2 id="executive-summary"><em>Executive summary</em></h2>
<h2 id="introduction">Introduction</h2>
<h2 id="nephrotic-syndrome-ns-is-a-clinical-disorder-characterized-by-the-presence-of-massive-proteinuria-hypoalbuminaemia-and-oedema.-it-may-be-idiopathic-or-secondary.-a-secondary-cause-must-be-sought-for-before-commencement-of-treatment-.">Nephrotic syndrome (NS) is a clinical disorder characterized by the presence of massive proteinuria, hypoalbuminaemia and oedema. It may be idiopathic or secondary. A secondary cause must be sought for before commencement of treatment .</h2>
<h2 id="idiopathic-ns-the-cause-is-usually-unknown-but-histologic-findings-include-minimal-change-disease-mcd-membranous-nephropathy-mn-and-focal-segmental-glomerulosclerosis-fsgs.-these-are-very-common-in-children-and-responsive-to-steroid-therapy-.-they-may-also-be-seen-in-adults.">Idiopathic NS: The cause is usually unknown but histologic findings include minimal change disease (MCD), membranous nephropathy (MN) and focal segmental glomerulosclerosis (FSGS). These are very common in children and responsive to steroid therapy . They may also be seen in adults.</h2>
<h2 id="secondary-ns-these-may-have-similar-histologic-features-as-idiopathic-ns-but-are-due-to-known-causes-such-as-viral-infections-e.g.-hiv-hbv-and-hcv-non-communicable-diseases-such-as-diabetes-mellitus-multiple-myeloma-and-amyloidosis-and-auto-immune-disorders-such-as-systemic-lupus-erythematosus.-secondary-ns-makes-up-a-small-fraction-of-ns-and-requires-treatment-of-the-underlying-cause.">Secondary NS: These may have similar histologic features as idiopathic NS but are due to known causes such as viral infections e.g. HIV, HBV and HCV , non-communicable diseases such as diabetes mellitus, multiple myeloma and amyloidosis; and auto-immune disorders such as systemic lupus erythematosus. Secondary NS makes up a small fraction of NS and requires treatment of the underlying cause.</h2>
<h3 id="target-users">Target users</h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Doctors</p>
</div></li>
</ul>
<h3 id="target-area-of-use">Target area of use </h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Ward</p>
</div></li>
</ul>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Outpatient department</p>
</div></li>
</ul>
<h3 id="key-areas-of-focus-new-additions-changes">Key areas of focus / New additions / Changes </h3>
<p>This guideline focuses on the diagnosis and treatment of idiopathic nephrotic syndrome in adults and children. Treatment of secondary nephrotic syndrome requires treatment of the underlying cause. These can be found in the related specific guideline .</p>
<p>Treatment of nephrotic syndrome may take up to 3 months in children and 7 months in adults.</p>
<h3 id="limitations">Limitations </h3>
<p>Cases of relapse and steroid resistance require referral to nephrologist</p>
<h2 id="presenting-symptoms-and-signs">Presenting symptoms and signs</h2>
<p>These include:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Passage of frothy urine</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Leg swelling</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Facial swelling</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Abdominal swelling</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Breathlessness</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Dizziness</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Reduction in urine output</p>
</div></li>
</ul>
<h3 id="important-warning-features">Important warning features :</h3>
<p>These findings may indicate a diagnosis other than NS :</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Macroscopic haematuria – coke-colored urine or blood in urine</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Elevated blood pressure</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Jaundice</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Paroxysmal nocturnal dyspnea</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Raised jugular venous pressure</p>
</div></li>
</ul>
<p><strong>Diagnosis</strong></p>
<p>Diagnosis of NS is made when the following are present:</p>
<ol type="1">
<li><div data-custom-style="List Paragraph">
<p>Oedema</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Urine dipstick showing 3-4+ protein OR urine protein/creatinine ratio ≥ 2 g/g OR protein in 24-hour urine of ≥ 3.0 g</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Hypoalbuminaemia (&lt; 25 g/L).</p>
</div></li>
</ol>
<p>Hyperlipidaemia (high LDL cholesterol levels) may be present but is not necessary for diagnosis. In view of this, there is no indication to check the lipid profile.</p>
<h2 id="examination-findings">Examination findings</h2>
<p>The most common examination findings include</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Peripheral oedema</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Periorbital oedema</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Ascites</p>
</div></li>
</ul>
<p><strong>Investigations</strong></p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Urine dipstick</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Early morning urine protein/creatinine ratio</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Serum creatinine</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Serum albumin</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Serum lipid profile</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Plain chest X-ray</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>FBC</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Renal biopsy</p>
</div></li>
</ul>
<blockquote>
<p>Other tests to rule out secondary causes of NS:</p>
</blockquote>
<ul>
<li><div data-custom-style="List Paragraph">
<p>HIV Serology</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Hepatitis serology</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Serum or urine protein electrophoresis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Blood glucose</p>
</div></li>
</ul>
<h2 id="management">Management </h2>
<h3 id="for-children-with-ns">For children with NS </h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Admit child with first presentation of NS.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Oedema: Reduce salt intake and maintain strict fluid balance. If oedema is symptomatic there may be need to give IV frusemide 1 mg/kg OD (not more than 40 mg per dose).</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Prophylaxis against complications:</p>
</div>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Infections: Oral penicillin V at 125 mg BD if under 5 years, or 250 mg BD if over 5 years. This should continue until oedema subsides. If the child is profoundly ill or appears to have sepsis use IV Ceftriaxone 50 mg/kg OD (max 2g)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Prednisolone - induced gastritis: Oral omeprazole 0.5 - 1.5 mg OD (max 40 mg OD )</p>
</div></li>
</ul></li>
<li><div data-custom-style="List Paragraph">
<p>Immunosuppressive therapy: To induce remission, followed by a slow wean to reduce risk of relapse: Oral prednisolone 60 mg/m<sup>2</sup>/day or 2mg /kg (max 80 mg) OD for 4 weeks, then 40 mg/m<sup>2</sup>/alternate days (max 60 mg) for 4 weeks, then 20 mg/m<sup>2</sup>/alternate days for 10 days, then 10 mg/m<sup>2</sup>/on alternate days for 10 days, then 5 mg/m<sup>2</sup>/alternate days for 10 days, then cease.</p>
</div></li>
</ul>
<h3 id="for-adults-with-ns">For adults with NS </h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Oedema: Restrict dietary sodium to less than 3 g per day and fluid to less than 1,500 mL per day. Strict fluid balance.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Treat oedema with loop diuretics – oral or IV – depending on degree of oedema. The aim is to reduce patient’s weight by 0.5-1 kg /day.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Proteinuria: Give ACE inhibitors regardless of blood pressure. Start at low dose.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>There is no evidence to support the use of corticosteroids in adult NS. However, it is recommended based on histological reports. Patients with Idiopathic NS from MCD and FSGS may be placed on prednisolone 1 mg/kg/day (max 80 mg/day) for 4 weeks (or continued over 16 weeks) with treatment tapered off over 6 months.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Treat secondary cause of NS if present.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Anticoagulation, statin therapy and infection prophylaxis are not recommended for adults. However, treat infections, if they occur and provide prophylaxis for patients at high risk of thromboembolic events.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Refer patients who still have proteinuria after treatment to nephrologist for expert management.</p>
</div></li>
</ul>
<h3 id="special-issues-and-complications">Special issues and complications </h3>
<p><strong>Remission</strong> is present when the urine dipstick protein ≤ 1+ on 3 consecutive days after completion of treatment course.</p>
<p><strong>Relapse</strong> is defined as the presence of oedema plus urine dipstick protein of ≥ 3+ for 3 consecutive days after remission. This requirements the re-commencement of steroid therapy.</p>
<p><strong>Steroid resistance</strong> exists when urine dipstick protein ≥ 3+ for 3 consecutive days with oedema, after a 4-week course of treatment with steroids in adults and 3 month course in children.</p>
<p>In the case of relapse or steroid resistance, consider referring patient to nephrologist for specialist care.</p>
<p>Complications include hypovolaemia, infection and thrombosis and acute kidney injury.</p>
<h2 id="key-issues-for-nursing-care">Key Issues for Nursing care</h2>
<h2 id="while-a-patient-is-on-admission-the-following-should-be-done">While a patient is on admission the following should be done:</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Daily urine dipstick measurement</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Daily weighing</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Blood pressure monitoring</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Strict fluid balance chart.</p>
</div></li>
</ul>
<h2 id="references">References</h2>
<p>National Kidney Foundation. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012(2)</p>
<p>Kodner C. Nephrotic syndrome in adults: diagnosis and management. American family physician. 2009 Nov 15;80(10).</p>
<table>
<thead>
<tr class="header">
<th><strong>Written by:</strong></th>
<th>Name: Orighomisan Agboghoroma</th>
<th>Date: 15 November 2018</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Reviewed by:</strong></td>
<td>Name: Karen Forrest</td>
<td>Date: 16 November 2018</td>
</tr>
<tr class="even">
<td><strong>Version:</strong></td>
<td><strong>Change history:</strong></td>
<td><strong>Review due date:</strong></td>
</tr>
<tr class="odd">
<td>1.0</td>
<td>New document</td>
<td>31 January 2021</td>
</tr>
<tr class="even">
<td>1.1</td>
<td>Executive summary added</td>
<td>31 January 2021</td>
</tr>
<tr class="odd">
<td>Review Comments (<em>if applicable)</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</article>
</body>
</html>
